表柔比星用于胃癌的II期试验。
Phase II trial of epirubicin in gastric cancer.
作者信息
Scarffe J H, Kenny J B, Johnson R J, Owens S E, Giles G R, Leveson S H, Maley W V
出版信息
Cancer Treat Rep. 1985 Nov;69(11):1275-7.
PMID:3867402
Abstract
Patients with advanced inoperable or recurrent adenocarcinoma of the stomach received an iv bolus of epirubicin (75 mg/m2) every 3 weeks. Partial responses were observed in four of 24 evaluable patients (17%). Treatment was generally well tolerated; a drop in left ventricular ejection fraction was observed in one patient who had received 450 mg/m2 of epirubicin.
摘要
患有晚期无法手术或复发性胃腺癌的患者每3周接受一次表柔比星静脉推注（75毫克/平方米）。24例可评估患者中有4例（17%）观察到部分缓解。治疗一般耐受性良好；1例接受了450毫克/平方米表柔比星的患者观察到左心室射血分数下降。
Zotero 插件